Hematologist
CION Cancer Clinics
When CAR-T cells cannot be made: your next steps | CION Cancer Clinics
If your CAR-T cells fail to grow or miss a quality check, you still have options. The team will usually consider a second collection and remake, whether the cells made can still be used, a different treatment, or a clinical trial. Which one fits depends on why the product failed and how you are today. This page explains each option and the questions to ask. At CION Cancer Clinics, our haematology team assesses whether a transplant or CAR-T fits your situation and coordinates care with qualified centres.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What happens if your CAR-T cells cannot be made?
- Why do CAR-T cells sometimes fail to grow?
- What usually happens in the days after you are told?
- Which next step might suit you?
- What do families wrongly believe after a failed attempt?
- What do the words in the letter mean?
- What can this page not tell you, and what should you ask?
- Common questions about CAR-T manufacturing failure
The short answer
What happens if your CAR-T cells cannot be made?
If the laboratory cannot make your CAR-T cells, it is not the end of the road. Most families are offered one of four next steps: a second collection and a fresh attempt, a careful look at whether the cells that were made can still be used, a different treatment, or a clinical trial.
What "failure" usually means
CAR-T cells are made from your own white cells. They are collected, sent to a laboratory, changed so they can find the cancer, and grown in large numbers. At the end, the product is tested against strict quality rules. Sometimes too few cells grow. Sometimes the cells grow but miss one of the quality measures. Both are called a manufacturing failure, but they lead to different conversations.
Why it feels so hard
You have usually waited weeks, and you may have had bridging treatment to hold the cancer back during that wait. Hearing that the cells are not ready can feel like losing that time. The team's first job is to check how you are now, because your health today decides which next step is realistic.
This does not happen to most people, but it does happen, and it is worth asking about before collection so you are not hearing it for the first time on a bad day.Reasons
Why do CAR-T cells sometimes fail to grow?
Nobody did anything wrong. The reasons are mostly about what the body has been through before collection.
Too few healthy T cells
T cells are the white cells used to make the product. Several rounds of earlier chemotherapy can leave too few of them, or leave them tired and slow to grow in the laboratory.
The cells miss a quality test
The finished product must pass checks on cell count, how many cells carry the new receptor, and whether it is sterile. Missing one check blocks routine release.
Your report may say
- Out of specification
- Insufficient yield
The disease moves during the wait
Sometimes the cells are fine but the patient becomes too unwell, or the cancer grows fast enough that the plan has to change before the cells can be given.
Transport and handling
The cells travel frozen between the collection centre and the laboratory. A problem with timing or temperature is uncommon, but it can mean starting again.
Not sure whether this applies to you?
Ask an oncologistAfter the news
What usually happens in the days after you are told?
-
The team explains the exact reason
Ask for it in writing. "Not enough cells" and "failed one quality check" point to different options.
-
Your health and disease are checked again
Blood counts, a scan if needed, and an honest look at how you are coping. This sets what is still possible.
-
Bridging treatment is reviewed
If the cancer needs holding back for longer, the team decides what to give. Do not stop or change any medicine on your own while you wait.
-
A second collection is considered
If your counts allow it, your cells may be collected again for a new attempt. The team weighs whether the reason for failure is likely to repeat.
-
A new plan is agreed with you
A remake, a different treatment or a trial. Bring the family member who shares decisions with you to this meeting.
Side by side
Which next step might suit you?
Option
Who it may suit, and who it may not
Second collection and remake
People whose counts have recovered and whose disease is stable enough to wait again
Using a product that narrowly missed a check
Only where the maker, the centre and the rules allow it; not possible for every product
A different treatment, such as a bispecific antibody or a transplant
People who cannot wait for another attempt, or whose earlier cells are unlikely to grow
A clinical trial
People who meet the trial's entry rules and can travel for it
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
What do families wrongly believe after a failed attempt?
"The cells failed, so his body is too weak for any treatment."
A failed product says something about the cells collected on one day. It does not decide what else your body can take. Many people who could not receive CAR-T go on to other treatment, and your haematologist will look at your whole picture, not one result.
"We must have done something wrong before collection."
Food, rest or prayer before the collection day did not cause this. The usual reasons are earlier treatment and the disease itself. Blaming yourself takes energy you need for the next decision.
"A second try will just fail again."
Sometimes it does, and the team will say so honestly if the reason is likely to repeat. But a later collection, after counts recover, can grow well. It depends on why the first one failed.
"We will have to pay the full amount again."
This varies by maker, by centre and by your scheme or insurer. Some arrangements cover a remake. Ask the treating centre to explain the terms in writing before you agree to anything.
On your paperwork
What do the words in the letter mean?
- Apheresis
- The collection day. Blood is drawn through a machine that keeps the white cells and returns the rest to you.
- Out of specification
- The finished cells missed at least one of the quality measures they must meet before routine release.
- Bridging therapy
- Treatment given during the wait to keep the cancer in check until the cells are ready.
- Lymphodepletion
- A short course of chemotherapy just before the cells go in, to make room for them. It is not given until the cells are confirmed ready.
- Vein-to-vein time
- The whole wait, from the collection day to the day the cells are put back into your vein.
Being straight with you
What can this page not tell you, and what should you ask?
This page cannot tell you which option is right for you, or how any of them is likely to go. That depends on the type of blood cancer, what treatment you have already had, your counts, and how you are today. Only the team that has your reports can weigh those together.
Questions worth writing down
Why exactly did the product fail? Is that reason likely to repeat? Can my cells be collected again, and when? What bridging treatment will I have while we decide? Is there a trial I could join? What will a remake cost us, and who pays for it? What happens if we choose not to try again?
How CION can help
CION does not make or give CAR-T cells. Our haematology team can review your reports, present your case at a tumour board, where several specialists decide together, and help you understand the options and reach a qualified centre for the next step. If you want a second opinion before choosing, that is a reasonable thing to ask for.
Bring the manufacturing letter, your latest blood reports and your scan reports to any appointment.Questions we are asked
Common questions about CAR-T manufacturing failure
How common is it for CAR-T cells to fail?
It is uncommon, and most people's cells are made successfully. The chance is higher when someone has had many earlier treatments or very low counts at collection. Ask your treating centre how often it sees this with the product planned for you, since it differs between products and between groups of patients.
Will I have to go through apheresis again?
If a remake is chosen, usually yes. The collection is repeated once your counts are good enough. It is the same process as the first time: a few hours connected to a machine, awake, usually as a day visit. Your team will tell you whether your counts allow it and how long to wait.
Can the cancer grow while we wait for a second attempt?
It can, which is why the team reviews your disease and bridging treatment as soon as the failure is known. If the cancer is moving fast, they may advise a different treatment rather than another long wait. That is a judgement about your situation, not a sign that they have given up.
Can they use the cells that were made even if a test failed?
Sometimes, but not always. Whether a product that missed a quality measure can still be given depends on which measure, the maker's rules and the regulator's rules. The treating haematologist will explain the risk and ask for your consent. It is not something the family can request as a routine choice.
What treatments are there if CAR-T is not possible?
Depending on the blood cancer, options may include other immunotherapy such as bispecific antibodies, further chemotherapy, targeted medicines, a stem cell transplant or a clinical trial. Some people choose care focused on comfort. Your haematologist will tell you which of these fit your disease and your health.
Does the lymphodepleting chemotherapy go ahead anyway?
Normally no. That short course of chemotherapy is only started once the cells are confirmed ready to be given. If the product fails, it is held back. If you have already started it, tell your team straight away and follow their instructions, rather than stopping anything yourself.
How do I tell my father the cells did not grow?
Simply and with the facts you have. He probably senses something is wrong already. Tell him that the cells did not grow well enough, that this happens, and that the team is looking at the next step. Ask the doctor to explain it with the family present if that feels easier for everyone.
Can CION arrange the next step for us?
CION's haematology team can review your reports, discuss your case at a tumour board and help you reach a qualified centre for a remake, a transplant opinion, a trial or other treatment. We do not make CAR-T cells ourselves. Call the helpline with your latest reports and we will tell you how we can help.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Patient stories
Hear it from people we have treated
Every story is a video, in the patient's own words. Nothing here is a written testimonial.
Accreditation and empanelment
- NABH
- NABL
- ISO 9001:2015
- ArogyaSri empanelled
- CGHS accepted
- ECHS accepted
- EHS accepted
- Major cashless insurers
Paying for it
Insurance, schemes and payment
What you actually pay usually differs a great deal from the sticker figure.
AarogyasriEmpanelled. Bring the card and a referral where you have one.
CGHS / ECHS / EHSAccepted at CION centres for eligible treatment.
Cashless insuranceMost major insurers are empanelled. Pre-authorisation is handled by our desk.
Self-payItemised estimate given before treatment starts. No EMI scheme exists.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. A haematology consultation can be booked at any of these centres through one helpline, and your team will tell you where each test or treatment takes place.
Warangal
Vizag
Sources
- National Cancer Institute — CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers
- Cancer Research UK — CAR T-cell therapy
- Leukemia & Lymphoma Society — Chimeric Antigen Receptor (CAR) T-Cell Therapy
- American Cancer Society — CAR T-cell Therapy and Its Side Effects
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
The Manufacturing Wait and What Happens MeanwhileBridging treatment while the cells are being madeApheresis for CAR-T: The Cell Collection DayWhat a second collection involvesCAR-T or Transplant: Choosing Between ThemIf a transplant becomes the next optionCAR-T: The GapsEvery stage of CAR-T, from referral to follow-up
Talk to us
Told your CAR-T cells could not be made?
Share your reports with us. CION's haematology team will review them, discuss your case at a tumour board and help you reach the right centre for the next step.